The “New” Way Forward: DelveInsight’s Oncology-Based MOA Pipeline Reports

Delhi, India, November 28, 2014 --(PR.com)-- After successfully launching a huge portfolio of Pipeline Reports under brand name Pharm Insights covering 700+ Mechanism of Action reports; Delhi based DelveInsight is now venturing into the market for Oncologic drugs which is expected to be among the top revenue generating industries worldwide till 2020 through its Oncology based Mechanism Of Action (MOA) Reports which provide comprehensive review of current trends in the oncology market along with updated information on the latest innovations in therapeutics based on a particular Mechanism Of Action (MOA).

DelveInsight's released Oncology based Mechanism of Action (MOA) reports provides the targets-mode of action based information-across all the therapy under research work, pipeline products across all the companies, current technology, molecule type, stage, company finances, comparative analysis and therapeutic assessment at every step. These Reports highlights therapeutic targets and their mode of action; for instance Breast Cancer targets: PI3 Kinase inhibitors, Human Epidermal Growth Factor Receptor 4 (HER-4/ERBB4) inhibitors, etc. and Lung Cancer Targets: Cyclin Dependent Kinase (CDKs) inhibitors, Platelet Derived Growth Factor (PDGF) inhibitors and many more. Moreover these reports can be customized to include any specific information.

DelveInsight's reports consist of 80+ MOA reports on the current “hot” oncology targets for which the industry’s collective pipeline is brimming with drugs like on Breast cancer (28%), Lung cancer (29%), Prostate cancer, Colorectal cancer and Melanoma of which Breast cancer and Lung cancer collectively account for 57% of cancer drugs in pipeline. Thus, making it the most known among the American clients.

These reports are available through leading resellers such as Report Linker, Report Buyer, Market Publishers, Research and Markets, Market Research, ASD Media and Report stack .